These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 36925702)

  • 1. Optimization of CRISPR-Cas system for clinical cancer therapy.
    Meng X; Wu TG; Lou QY; Niu KY; Jiang L; Xiao QZ; Xu T; Zhang L
    Bioeng Transl Med; 2023 Mar; 8(2):e10474. PubMed ID: 36925702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research advances on the development and application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein system].
    Tan JJ; Peng YZ; Huang GT
    Zhonghua Shao Shang Za Zhi; 2021 Jul; 37(7):681-687. PubMed ID: 34304411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research.
    Yang Y; Xu J; Ge S; Lai L
    Front Med (Lausanne); 2021; 8():649896. PubMed ID: 33748164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials and promising preclinical applications of CRISPR/Cas gene editing.
    Çerçi B; Uzay IA; Kara MK; Dinçer P
    Life Sci; 2023 Jan; 312():121204. PubMed ID: 36403643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.
    Liu W; Li L; Jiang J; Wu M; Lin P
    Precis Clin Med; 2021 Sep; 4(3):179-191. PubMed ID: 34541453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome Editing in Bacteria: CRISPR-Cas and Beyond.
    Arroyo-Olarte RD; Bravo Rodríguez R; Morales-Ríos E
    Microorganisms; 2021 Apr; 9(4):. PubMed ID: 33920749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement.
    Li C; Brant E; Budak H; Zhang B
    J Zhejiang Univ Sci B; 2021 Apr; 22(4):253-284. PubMed ID: 33835761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR Systems Suitable for Single AAV Vector Delivery.
    Stevanovic M; Piotter E; McClements ME; MacLaren RE
    Curr Gene Ther; 2022; 22(1):1-14. PubMed ID: 34620062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress and challenges towards CRISPR/Cas clinical translation.
    Rosenblum D; Gutkin A; Dammes N; Peer D
    Adv Drug Deliv Rev; 2020; 154-155():176-186. PubMed ID: 32659256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CRISPR-Cas in advancing precision periodontics.
    Barbour A; Glogauer J; Grinfeld L; Ostadsharif Memar R; Fine N; Tenenbaum H; Glogauer M
    J Periodontal Res; 2021 Jun; 56(3):454-461. PubMed ID: 33452819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas gene therapy.
    Zhang B
    J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.
    Feng S; Wang Z; Li A; Xie X; Liu J; Li S; Li Y; Wang B; Hu L; Yang L; Guo T
    Front Cell Dev Biol; 2021; 9():803252. PubMed ID: 35198566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient expression of multiple guide RNAs for CRISPR/Cas genome editing.
    Hsieh-Feng V; Yang Y
    aBIOTECH; 2020 Apr; 1(2):123-134. PubMed ID: 36304720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in structural studies of the CRISPR-Cas-mediated genome editing tools.
    Zhu Y; Huang Z
    Natl Sci Rev; 2019 May; 6(3):438-451. PubMed ID: 34691893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems.
    Hejabi F; Abbaszadeh MS; Taji S; O'Neill A; Farjadian F; Doroudian M
    Front Chem; 2022; 10():957572. PubMed ID: 36092658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CRISPR-Cas toolbox and gene editing technologies.
    Liu G; Lin Q; Jin S; Gao C
    Mol Cell; 2022 Jan; 82(2):333-347. PubMed ID: 34968414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for Optimization of the Clustered Regularly Interspaced Short Palindromic Repeat-Based Genome Editing System for Enhanced Editing Specificity.
    Wang YM; Wang HZ; Jian YZ; Luo ZT; Shao HW; Zhang WF
    Hum Gene Ther; 2022 Apr; 33(7-8):358-370. PubMed ID: 34963339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic modulation of gene expression in the disease state: Treatment strategies and approaches for the development of next-generation of the epigenetic drugs.
    Rittiner J; Cumaran M; Malhotra S; Kantor B
    Front Bioeng Biotechnol; 2022; 10():1035543. PubMed ID: 36324900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.